# US 2011/0178043 A1 · Inhibitors of the mevalonate pathway of streptococcus pneumoniae

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0178043 A1
- Document ID: US20110178043A1
- Status: Published application
- Kind: A1
- Application number: 11/983,584
- Filed: 2007-11-09
- Published: 2011-07-21
- Earliest claimed: 2006-11-09
- Assignees: Northwestern University
- Inventors: Richard B. Silverman; Takashi Kudoh
- Web page: https://patentgrep.com/patent/US20110178043A1

## CPC

- C07F 9/098: {Esters of polyphosphoric acids or anhydrides}
- A61P 31/04: Antibacterial agents
- C07C 59/11: containing rings
- C07C 59/44: Ricinoleic acid
- C07D 319/12: not condensed with other rings
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds and related methods as can be used for selective mevalonate pathway inhibitors.

## Claims

### Claim 1

A mevalonate pathway inhibitor compound of a formula
wherein R1 is selected from C2 to about C6 alkyl, C2 to about C6 substituted alkyl, C2 to about C6 alkenyl, C2 to about C6 substituted alkenyl, C2 to about C6 alkynyl, C2 to about C6 substituted alkynyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl moieties; and R2 and R2′ are independently selected from H, monophosphate and diphosphate moieties; and salts, esters, hydrates and solvates thereof.

### Claim 2 (depends on 1)

The inhibitor compound of claim 1 wherein R1 is selected from C2 to about C4 alkyl moieties.

### Claim 3 (depends on 2)

The inhibitor compound of claim 2 wherein R1 is selected from cyclopropyl and methylenecyclopropyl moieties.

### Claim 4 (depends on 1)

The inhibitor compound of claim 1 wherein R1 is selected from vinyl and acetylenyl moieties.

### Claim 5 (depends on 1)

The inhibitor compound of claim 1 wherein R2 and R2′ are H.

### Claim 6 (depends on 1)

The inhibitor compound of claim 1 wherein R2′ is H and said compound comprises the intramolecular cyclization product thereof.

### Claim 7 (depends on 1)

The inhibitor compound of claim 1 contacting an enzyme in a mevalonate biosynthetic pathway.

### Claim 8

A mevalonate pathway inhibitor compound of a formula
wherein R1 is selected from C2 to about C6 alkyl, C2 to about C6 substituted alkyl, C2 to about C6 alkenyl, C2 to about C6 substituted alkenyl, C2 to about C6 alkynyl, and C2 to about C6 substituted alkynyl moieties; and salts, esters, hydrates and solvates thereof.

### Claim 9 (depends on 8)

The inhibitor compound of claim 8 where in is selected from C2 to about C4 alkyl moieties.

### Claim 10 (depends on 9)

The inhibitor compound of claim 9 wherein R1 is selected from cyclopropyl and methylenecyclopropyl moieties.

### Claim 11 (depends on 8)

The inhibitor compound of claim 8 wherein R1 is selected from vinyl and acetylenyl moieties.

### Claim 12 (depends on 8)

The inhibitor compound of claim 8 interacting with an enzyme of a mevalonate biosynthetic pathway.

### Claim 13 (depends on 12)

The inhibitor compound of claim 12 wherein said enzyme is selected from a mevalonate kinase, a diphosphomevalonate decarboxylase and combinations thereof.

### Claim 14 (depends on 13)

The inhibitor compound of claim 13 wherein said enzyme is of Streptococcus pneumoniae.

### Claim 15

A method of treating Streptococcus pneumoniae comprising contacting Streptococcus pneumoniae with an effective amount of a compound of formula
wherein R1 is selected from C2 to about C6 alkyl, C2 to about C6 substituted alkyl, C2 to about C6 alkenyl, C2 to about C6 substituted alkenyl, C2 to about C6 alkynyl, and C2 to about C6 substituted alkynyl moieties; and salts, esters, hydrates and solvates thereof.

### Claim 16 (depends on 15)

The method of claim 15 wherein R1 is selected from C2 to about C4 alkyl moieties.

### Claim 17 (depends on 16)

The method of claim 16 wherein R1 is selected from cyclopropyl and methylenecyclopropyl moieties.

### Claim 18 (depends on 15)

The method of claim 15 wherein R1 is selected from vinyl and acetylenyl moieties.

### Claim 19

A method of using a C-3 substituent of a mevalonate analog compound to affect an enzyme in a mevalonate biosynthetic pathway, said method comprising contacting a mevalonate pathway enzyme with an effective amount of a compound of a formula
wherein R1 is selected from C2 to about C6 alkyl, C2 to about C6 substituted alkyl, C2 to about C6 alkenyl, C2 to about C6 substituted alkenyl, C2 to about C6 alkynyl, C2 to about C6 substituted alkynyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl moieties; and R2 and R2′ are independently selected from H, monophosphate and diphosphate moieties; and salts, esters, hydrates and solvates thereof.

### Claim 20 (depends on 19)

The method of claim 19 wherein R1 is selected from C2 to about C4 alkyl moieties.

### Claim 21 (depends on 20)

The method of claim 20 wherein R1 is selected from cyclopropyl and methylenecyclopropyl moieties.

### Claim 22 (depends on 19)

The method of claim 19 wherein R1 is selected from vinyl and acetylenyl moieties.

### Claim 23 (depends on 19)

The method of claim 19 wherein said compound is the hydrolysis product of a compound of a formula
said compound phosphorylated.

### Claim 24 (depends on 19)

The method of claim 19 wherein said enzyme is selected from a mevalonate kinase, a diphosphomevalonate decarboxylase and combinations thereof.

### Claim 25 (depends on 24)

The method of claim 24 wherein said enzyme is bacterial.
